NVX

Phillips 66, NOVONIX Sign Technology Development Agreement to Advance Production of Lithium-Ion Batteries in North America

Retrieved on: 
Wednesday, January 19, 2022
Other Manufacturing, Finance, Other Energy, Transport, Chemicals, Plastics, Oil, Gas, Professional Services, Manufacturing, Energy, Logistics, Supply Chain Management, Energy, Securities Exchange Act of 1934, Forward-looking statement, Research, Technology, Phillips, D, Innovation, NYSE, Growth, Safety, Intellectual property, ASX, U.S. Securities and Exchange Commission, OTC, Industry, NVX, Specialty, Phillips 66, Marketing, Twitter, Security (finance), Energy Independence and Security Act of 2007, Partnership, Securities Act of 1933, Electric battery, Phillips 66, NOVONIX, PHILLIPS 66, NOVONIX

Phillips 66 (NYSE: PSX) and NOVONIX Limited (ASX: NVX, OTC: NVNXF) today announced they have signed a technology development agreement to advance the production and commercialization of next-generation anode materials for lithium-ion batteries.

Key Points: 
  • Phillips 66 (NYSE: PSX) and NOVONIX Limited (ASX: NVX, OTC: NVNXF) today announced they have signed a technology development agreement to advance the production and commercialization of next-generation anode materials for lithium-ion batteries.
  • Phillips 66 became a major investor in NOVONIX in September of 2021, when it acquired a 16% stake in the company.
  • The investment is supporting NOVONIXs growth as it scales up production and develops new technologies for higher-performance energy storage applications.
  • Phillips 66 is a leading global manufacturer of specialty coke, a key precursor to the synthetic graphite anode material NOVONIX produces.

Final Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed Against Novavax, Inc. (NVAX)

Retrieved on: 
Monday, January 10, 2022
District, NVAX, LLP, Novavax COVID-19 vaccine, NASDAQ, District court, Lead, Food, The Washington Post, Fraud, Politico, Vaccine, News, COVID-19, FDA, Infection, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biotechnology, EUA, Private investigator, Pharmaceutical industry, Animal, Architecture, NVX, Novavax

Kessler Topaz Meltzer & Check, LLP encourages Novavax investors who have suffered significant losses to contact the firm directly to acquire more information.

Key Points: 
  • Kessler Topaz Meltzer & Check, LLP encourages Novavax investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

NVAX DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Novavax, Inc. of Deadline in Securities Fraud Class Action Lawsuit

Retrieved on: 
Saturday, January 8, 2022
Legal, Professional Services, Fraud, NVAX, Vaccine, COVID-19, Lead, Food, Regulation of tobacco by the U.S. Food and Drug Administration, The Washington Post, Infection, NASDAQ, LLP, FDA, News, EUA, Politico, Biotechnology, Novavax COVID-19 vaccine, Private investigator, Pharmaceutical industry, Animal, NVX, Novavax

The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. (Novavax) ( NASDAQ: NVAX ).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. (Novavax) ( NASDAQ: NVAX ).
  • Kessler Topaz Meltzer & Check, LLP encourages Novavax investors who have suffered significant losses to contact the firm directly to acquire more information.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Novavax, Inc. (NVAX)

Retrieved on: 
Friday, January 7, 2022
Legal, Professional Services, Time, NVX, NVAX, Court, Company, Novavax, Law, The Washington Post, Lists of schools in England, Twitter, NASDAQ, Suite, News, EUA, Novavax COVID-19 vaccine, Pharmaceutical industry, Animal, Politico

On this news, Novavaxs stock price fell $15.50 per share, or 8.81%, to close at $160.50 per share on May 10, 2021.

Key Points: 
  • On this news, Novavaxs stock price fell $15.50 per share, or 8.81%, to close at $160.50 per share on May 10, 2021.
  • The stock price continued to decline $22.32 per share, or 13.91%, to close at $138.18 per share on May 11, 2021, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

 NOVONIX Commences Process for Nasdaq Listing

Retrieved on: 
Friday, January 7, 2022
Other Energy, Other Manufacturing, Hardware, Energy, Engineering, Technology, Manufacturing, Other Technology, NVX, BNY Mellon, Program, ADR, Securities Act of 1933, Bank, Review, Company, Australian Securities Exchange, American depositary receipt, U.S. Securities and Exchange Commission, RET, OTCQX, Level, CEO, SEC, Level 2, State Sponsors of Terrorism (U.S. list), EV, Sale, ASX, Industry, USN, Admiral, Security (finance), Renewable energy, Nasdaq

NOVONIX Limited (ASX: NVX, OTCQX: NVNXF) (NOVONIX or the Company), today announces the commencement of the process to list its securities on the Nasdaq Stock Market (Nasdaq).

Key Points: 
  • NOVONIX Limited (ASX: NVX, OTCQX: NVNXF) (NOVONIX or the Company), today announces the commencement of the process to list its securities on the Nasdaq Stock Market (Nasdaq).
  • As announced to the Australian Securities Exchange ("ASX") on 10 May 2021, NOVONIX has been exploring a secondary listing of its securities on Nasdaq.
  • The U.S. listing is expected to take place after the SEC and Nasdaq have completed their review process and upon effectiveness of the registration statement.
  • The establishment of the program by NOVONIX is not a public offering or issuance of new NOVONIX ordinary shares.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Novavax, Inc. (NVAX)

Retrieved on: 
Wednesday, January 5, 2022
Time, NVX, NVAX, GPM, Court, Company, Novavax, The Washington Post, Lists of schools in England, NASDAQ, Suite, News, GLOBE, EUA, Novavax COVID-19 vaccine, Pharmaceutical industry, Animal, Politico

On this news, Novavaxs stock price fell $15.50 per share, or 8.81%, to close at $160.50 per share on May 10, 2021.

Key Points: 
  • On this news, Novavaxs stock price fell $15.50 per share, or 8.81%, to close at $160.50 per share on May 10, 2021.
  • The stock price continued to decline $22.32 per share, or 13.91%, to close at $138.18 per share on May 11, 2021, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Novavax, Inc. of Class Action Lawsuit and Upcoming Deadline – NVAX

Retrieved on: 
Tuesday, January 4, 2022
NVAX, Vaccine, Lists of action films, Pomerantz, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, Court, Southern Division, SEC Rule 10b-5, The Washington Post, Lists of schools in England, Infection, Securities Exchange Act of 1934, Person, NASDAQ, LLP, Complaint, News, Ext, GLOBE, EUA, Novavax, District court, District, Biotechnology, Novavax COVID-19 vaccine, Security (finance), Pharmaceutical industry, Cryptocurrency, Animal, NVX, Politico

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment Novavax, Inc. of Class Action Lawsuit and Upcoming Deadline – NVAX

Retrieved on: 
Monday, December 27, 2021
The Washington Post, Company, Pomerantz, NVAX, Food, Securities Exchange Act of 1934, Novavax COVID-19 vaccine, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biotechnology, Vaccine, Lists of action films, Ext, EUA, Southern Division, NASDAQ, News, Novavax, District, District court, Lists of schools in England, GLOBE, Complaint, SEC Rule 10b-5, Court, LLP, Person, Security (finance), Pharmaceutical industry, Cryptocurrency, Animal, Politico, NVX

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

NOVAVAX, INC. (NASDAQ: NVAX) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Novavax, Inc.

Retrieved on: 
Monday, December 27, 2021
COVID-19, The Washington Post, Company, The Legal 500, Labour government, NVAX, Food, Securities Exchange Act of 1934, Novavax COVID-19 vaccine, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biotechnology, Vaccine, EUA, NASDAQ, NVX, News, District, District court, Lists of schools in England, Advertising, GLOBE, Court, LLP, Security (finance), Pharmaceutical industry, Politico, Novavax

If you purchased or otherwise acquired Novavax securities, and/or would like to discuss your legal rights and options, please visit Novavax Inc.

Key Points: 
  • If you purchased or otherwise acquired Novavax securities, and/or would like to discuss your legal rights and options, please visit Novavax Inc.
  • Shareholder Class Action Lawsuit or contact Joe Seidman toll free at (877) 779-1414 or [email protected] .
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Novavax, Inc. (NVAX)

Retrieved on: 
Monday, December 27, 2021
Court, Novavax, The Washington Post, Suite, News, NASDAQ, NVX, Novavax COVID-19 vaccine, GLOBE, EUA, GPM, NVAX, Time, Lists of schools in England, Company, Pharmaceutical industry, Animal, Politico

On this news, Novavaxs stock price fell $15.50 per share, or 8.81%, to close at $160.50 per share on May 10, 2021.

Key Points: 
  • On this news, Novavaxs stock price fell $15.50 per share, or 8.81%, to close at $160.50 per share on May 10, 2021.
  • The stock price continued to decline $22.32 per share, or 13.91%, to close at $138.18 per share on May 11, 2021, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles